Stereotactic Body Radiotherapy for Low-Risk Prostate Cancer: Five-Year Outcomes
Author Information
Author(s): Debra E Freeman, Christopher R King
Primary Institution: Naples Radiation Oncology, PA, USA; Department of Radiation Oncology, UCLA School of Medicine, CA, USA
Hypothesis
Does hypofractionated stereotactic body radiotherapy (SBRT) provide effective treatment outcomes for low-risk prostate cancer patients?
Conclusion
SBRT for localized prostate cancer shows high efficacy and safety with a 93% biochemical progression-free survival rate over five years.
Supporting Evidence
- The biochemical progression-free survival rate was 93% at five years.
- No grade 4 toxicities were reported.
- Only one late grade 3 genitourinary toxicity occurred.
Takeaway
This study shows that a special type of radiation treatment for prostate cancer works really well and has very few side effects.
Methodology
Patients received SBRT with CyberKnife in five fractions, and outcomes were assessed using Kaplan-Meier survival analysis.
Limitations
The study only included low-risk patients and had a relatively small sample size.
Participant Demographics
Median age was 66 years, with a range from 48 to 83 years; all patients had low-risk prostate cancer.
Statistical Information
P-Value
0.002
Confidence Interval
95% CI = 84.7% to 100%
Statistical Significance
p=0.002
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website